v3.20.1

Summary of significant transaction (Details) € / shares in Units, € in Thousands, $ in Millions |  |  |  |  |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 06, 2019 EUR (€) | Oct. 22, 2019 individual € / shares | Aug. 23, 2019 USD ($) | Aug. 23, 2019 EUR (€) | Jul. 14, 2019 € / shares | Jul. 14, 2019 USD ($) Program item | Jul. 13, 2019 | Aug. 31, 2019 | Dec. 31, 2019 USD ($) Milestone | Dec. 31, 2019 EUR (€) Milestone € / shares | Dec. 31, 2018 EUR (€) € / shares | Dec. 31, 2017 EUR (€) € / shares | Aug. 23, 2019 EUR (€)
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Global research and development collaboration term |  |  |  |  |  | 10 years |  |  |  |  |  |  |
Number of molecules | item |  |  |  |  |  | 6 |  |  |  |  |  |  |
Number of preclinical programs | Program |  |  |  |  |  | 20 |  |  |  |  |  |  |
Upfront payment received |  |  | $ 3,950 | € 3,569,800 |  |  |  |  |  |  |  |  |
Equity investment received |  |  | $ 1,100 |  |  |  |  |  |  |  |  |  | € 960,100
Additional equity investment from warrant exercise | € |  |  |  |  |  |  |  |  |  | € 17,167 | € 7,657 | € 5,288 |
Cost Share For Global Development Activities |  |  |  |  |  |  |  |  | 50.00% | 50.00% |  |  |
Number of directors represented as board members | individual |  | 2 |  |  |  |  |  |  |  |  |  |  |
Option rights period |  |  |  |  |  | 10 years |  |  |  |  |  |  |
Extension option rights period |  |  |  |  |  | 3 years |  |  |  |  |  |  |
Opt-in payments to be received for each program |  |  |  |  |  | $ 150 |  |  |  |  |  |  |
Average exercise price warrants | € / shares |  |  |  |  |  |  |  |  |  | € 22.8 | € 13.5 | € 14.4 |
GLPG 1690 License |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone fee |  |  |  |  |  | 325 |  |  |  |  |  |  |
GLPG 1972 License |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone fee |  |  |  |  |  | 550 |  |  |  |  |  |  |
Additional milestone fee |  |  |  |  |  | $ 200 |  |  |  |  |  |  |
Filgotinib drug license |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Future global development cost sharing ratio before predetermined level |  |  |  |  |  | 80.00% |  |  |  |  |  |  |
Development and regulatory milestones |  |  |  |  |  | $ 640 |  |  |  |  |  |  |
Sales based milestone payment |  |  |  |  |  | 600 |  |  |  |  |  |  |
Number of milestone payments achieved | Milestone |  |  |  |  |  |  |  |  | 2 | 2 |  |  |
Proceeds from milestone payments |  |  |  |  |  |  |  |  | $ 30 |  |  |  |
United States | GLPG 1972 License |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone fee on election of option to license |  |  |  |  |  | $ 250 |  |  |  |  |  |  |
France, Germany, Italy, Spain and the United Kingdom | Filgotinib drug license |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Profit sharing ratio |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Belgium, the Netherlands and Luxembourg | Filgotinib drug license |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Profit sharing ratio |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Cost Share For Global Development Activities |  |  | 20.00% |  |  |  |  |  |  |  |  |  | 20.00%
Minimum | Outside Europe |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty Percentage |  |  |  |  |  | 20.00% |  |  |  |  |  |  |
Minimum | Outside Europe | GLPG 1690 License |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty Percentage |  |  |  |  |  | 20.00% |  |  |  |  |  |  |
Minimum | Countries outside of Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain and the United Kingdom | Filgotinib drug license |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty Percentage |  |  |  |  |  | 20.00% |  | 20.00% |  |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Cost Share For Global Development Activities |  |  | 50.00% |  |  |  |  |  |  |  |  |  | 50.00%
Maximum | Outside Europe |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty Percentage |  |  |  |  |  | 24.00% |  |  |  |  |  |  |
Maximum | Outside Europe | GLPG 1690 License |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty Percentage |  |  |  |  |  | 24.00% |  |  |  |  |  |  |
Maximum | Countries outside of Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain and the United Kingdom | Filgotinib drug license |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty Percentage |  |  |  |  |  | 30.00% |  | 30.00% |  |  |  |  |
Gilead |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Share price | € / shares |  |  |  |  | € 140.59 |  |  |  |  |  |  |  |
Premium |  |  |  |  |  | 20.00% |  |  |  |  |  |  |
Volume of days |  |  |  |  |  | 30 days |  |  |  |  |  |  |
Percentage of stake | 25.10% |  |  |  |  | 22.04% | 12.30% |  | 25.84% | 25.84% |  |  |
Restricting Gilead's ability to seek to acquire |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Maximum share holding percentage |  | 29.90% |  |  |  |  |  |  |  |  |  |  |
Gilead | Filgotinib drug license |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Future global development cost sharing ratio before predetermined level |  |  |  |  |  | 20.00% |  |  |  |  |  |  |
Gilead | France, Germany, Italy, Spain and the United Kingdom | Filgotinib drug license |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Profit sharing ratio |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Gilead | Belgium, the Netherlands and Luxembourg | Filgotinib drug license |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Profit sharing ratio |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Gilead | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
EGM Conducted period |  | 57 months |  |  |  |  |  |  |  |  |  |  |
Gilead | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of stake |  | 29.90% |  |  |  |  |  |  |  |  |  |  |
EGM Conducted period |  | 59 months |  |  |  |  |  |  |  |  |  |  |
Warrant A | Gilead |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity investment from warrant exercise | € | € 368,000 |  |  |  |  |  |  |  |  |  |  |  |
Warrant B |  |  |  |  |  |  |  |  |  |  |  |  |
Summary of significant transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Multiplier used to calculate exercise price per share |  | 120.00% |  |  |  |  |  |  |  |  |  |  |
Initial term of the warrant |  | 5 years |  |  |  |  |  |  |  |  |  |  |
Average exercise price warrants | € / shares |  | € 140.59 |  |  |  |  |  |  |  |  |  |  |
Volume of days |  | 30 days |  |  |  |  |  |  |  |  |  |  |

X
- Definition The amount of additional milestone payments to be received up on met of secondary end points for the license. + References No definition available. + Details
Name: | glpg_AdditionalMilestoneFeeReceivedSecondaryEndPointsAreMetForLicense
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Arithmetic Mean 30 Day Daily Volume Weighted Average Trading Price of Entity, Multiplier, Exercise Price Per Share + References No definition available. + Details
Name: | glpg_ArithmeticMean30DayDailyVolumeWeightedAverageTradingPriceOfEntityMultiplierExercisePricePerShare
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the cost share mechanism for the future development activities, development and sales milestones and royalties. + References No definition available. + Details
Name: | glpg_CostShareForGlobalDevelopmentActivities
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the development and regulatory milestone payments. + References No definition available. + Details
Name: | glpg_DevelopmentAndRegulatoryMilestones
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The extended period for which sharing of cost if election of option to extend to outside domicile. + References No definition available. + Details
Name: | glpg_ExtendedProgramsOptionRightSharingPeriod
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period from which extra ordinary general meeting (EGM) will ne conducted from the close of subscription agreement. + References No definition available. + Details
Name: | glpg_ExtraOrdinaryGeneralMeetingConductPeriodFromDateOfClosingOfSubscriptionAgreement
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ratio at which future development cost will be shared before predetermined level. + References No definition available. + Details
Name: | glpg_FutureGlobalDevelopmentCostsSharingRatioBeforePredeterminedLevel
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period of contract for global research and collaboration. + References No definition available. + Details
Name: | glpg_GlobalResearchAndDevelopmentCollaborationTerm
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the initial term of the warrant. + References No definition available. + Details
Name: | glpg_InitialWarrantTerm
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum percentage of shares can hold up to certain period as per the agreement. + References No definition available. + Details
Name: | glpg_MaximumShareHoldingPercentageLimitationForCertainPeriod
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of milestone fee to be received if option to license. + References No definition available. + Details
Name: | glpg_MilestoneFeeReceivedElectionOfOptionToLicense
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of directors represented or appointed as board of directors. + References No definition available. + Details
Name: | glpg_NumberOfDirectorsRepresentedAsBoardOfDirectors
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of milestone payments achieved in current period. + References No definition available. + Details
Name: | glpg_NumberOfMilestonePaymentsAchievedInCurrentPeriod
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of molecules having right to access by the other party due to collaboration agreement. + References No definition available. + Details
Name: | glpg_NumberOfMoleculesHavingAccessToOtherParty
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of preclinical program having right to access by the other party due to collaboration agreement. + References No definition available. + Details
Name: | glpg_NumberOfPreclinicalProgramsHavingAccessToOtherParty
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of opt-in payments to be received for each program collaboration opted. + References No definition available. + Details
Name: | glpg_OptInPaymentsToBeReceivedForEachProgramCollaborationOpted
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The period of restrictions of change in ownership interest beyond certain levels. + References No definition available. + Details
Name: | glpg_PeriodOfRestrictionOnChangeInOwnershipInterestBeyondCertainLevels
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of premium shares was issued to other party. + References No definition available. + Details
Name: | glpg_PremiumPercentageOnSharePrice
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the exercise of warrants. + References No definition available. + Details
Name: | glpg_ProceedsFromExerciseOfWarrants
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of cash inflow from completion of milestone payments received. + References No definition available. + Details
Name: | glpg_ProceedsFromMilestonePayments
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ratio at which share of profits. + References No definition available. + Details
Name: | glpg_ProfitSharingRatio
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period for which sharing of cost if election of option to extend to outside domicile. + References No definition available. + Details
Name: | glpg_ProgramsOptionRightSharingPeriod
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of regulatory milestone payments received on approval of license. + References No definition available. + Details
Name: | glpg_RegulatoryMilestonePaymentsApprovalOfLicense
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of sales based milestone payments to be received. + References No definition available. + Details
Name: | glpg_SalesBasedMilestonePaymentsToBeReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent summary of significant transaction. + References No definition available. + Details
Name: | glpg_SummaryOfSignificantTransactionLineItems
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of tiered royalties percentage on sales. + References No definition available. + Details
Name: | glpg_TieredRoyaltiesPercentageOnNetSales
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash inflow received as upfront payment. + References No definition available. + Details
Name: | glpg_UpfrontPaymentReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The period of volume taken as base for calculation of weighted average share price. + References No definition available. + Details
Name: | glpg_WeightedAverageSharePriceCalculatedPeriod
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 24 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_24_a&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B16 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B16&doctype=Appendix&subtype=B -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 54 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_54_e&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2019-01-01 -Paragraph 45 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2019-en-r&anchor=para_45&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
Namespace Prefix: | ifrs-full_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The weighted average share price. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2019-01-01 -Paragraph 45 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2019-en-r&anchor=para_45_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_WeightedAverageSharePrice2019
Namespace Prefix: | ifrs-full_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=glpg_Glpg1690LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=glpg_Glpg1972LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=glpg_FilgotinibDrugLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=glpg_FranceGermanyItalySpainAndUnitedKingdomMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=glpg_BelgiumNetherlandsAndLuxembourgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=glpg_CountriesOutsideOfBelgiumFranceGermanyItalyLuxembourgNetherlandsSpainAndUnitedKingdomMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=glpg_WarrantaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=glpg_WarrantBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |